People | August 21, 2024
Wanbury appoints Pradeep Patni as CEO of India Formulation Business
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Kwality Pharma already has registration of 20 molecules from the units and 20 are under registration
Subscribe To Our Newsletter & Stay Updated
